We shouldn't put any stock into this yet. > "The preprint study funded by the companies determined that the vaccine’s effectiveness reached a high point of 96.

We shouldn't put any stock into this yet. > "The preprint study funded by the companies determined that the vaccine’s effectiveness reached a high point of 96.2 percent within two months after the second dose." The manufacturers are lobbying hard for booster shots, and there's no reason to trust a pre-print that they funded. Anyway, I think our next dose in the US will likely be updated for Delta instead of a booster.